Cardiorenal syndrome in acute decompensated heart failure

References

• Ronco C, McCullough P, Anker SD et al. Cardio–renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur. Heart J.31, 703–711 (2010).
   PubMed Web of Science ®Google Scholar
• Mullens W, Abrahams Z, Francis GS et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J. Am. Coll. Cardiol.53, 589–596 (2009).
   PubMed Web of Science ®Google Scholar
• Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the Prospective Outcomes Study in Heart Failure (POSH). Eur. Heart J.27, 1216–1222 (2006).
   PubMed Web of Science ®Google Scholar
• Metra M, Nodari S, Parrinello G et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur. J. Heart Fail.10, 188–195 (2008).
   PubMed Web of Science ®Google Scholar
• Voors AA, Davison BA, Felker GM et al. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Eur. J. Heart Fail.13, 961–967 (2011).
   Web of Science ®Google Scholar
• Goldberg A, Kogan E, Hammerman H, Markiewicz W, Aronson D. The impact of transient and persistent acute kidney injury on long-term outcomes after acute myocardial infarction. Kidney Int.76, 900–906 (2009).
   PubMed Web of Science ®Google Scholar
• Forman DE, Butler J, Wang Y et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J. Am. Coll. Cardiol.43, 61–67 (2004).
   PubMed Web of Science ®Google Scholar
• Aronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated heart failure. J. Card. Fail.16, 541–547 (2010).
   PubMed Web of Science ®Google Scholar
• Goldberg A, Hammerman H, Petcherski S et al. Inhospital and 1-year mortality of patients who develop worsening renal function following acute ST-elevation myocardial infarction. Am. Heart J.150, 330–337 (2005).
   PubMed Web of Science ®Google Scholar
• Akhter MW, Aronson D, Bitar F et al. Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am. J. Cardiol.94, 957–960 (2004).
   PubMed Web of Science ®Google Scholar
• Lassus JP, Nieminen MS, Peuhkurinen K et al. Markers of renal function and acute kidney injury in acute heart failure: definitions and impact on outcomes of the cardiorenal syndrome. Eur. Heart J.31(22), 2791–2798 (2010).
   PubMed Web of Science ®Google Scholar
• Gottlieb SS, Abraham W, Butler J et al. The prognostic importance of different definitions of worsening renal function in congestive heart failure. J. Card. Fail.8, 136–141 (2002).
   PubMed Web of Science ®Google Scholar
• Parikh CR, Coca SG, Wang Y, Masoudi FA, Krumholz HM. Long-term prognosis of acute kidney injury after acute myocardial infarction. Arch. Intern. Med.168, 987–995 (2008).
   PubMedGoogle Scholar
• Blair JE, Pang PS, Schrier RW et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur. Heart J.32, 2563–2572 (2011).
   PubMed Web of Science ®Google Scholar
• Smith GL, Lichtman JH, Bracken MB et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J. Am. Coll. Cardiol.47, 1987–1996 (2006).
   PubMed Web of Science ®Google Scholar
• Damman K, Navis G, Voors AA et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J. Card. Fail.13, 599–608 (2007).
   PubMed Web of Science ®Google Scholar
• Damman K, Jaarsma T, Voors AA, Navis G, Hillege HL, van Veldhuisen DJ. Both in- and out-hospital worsening of renal function predict outcome in patients with heart failure: results from the Coordinating Study Evaluating Outcome of Advising and Counseling in Heart Failure (COACH). Eur. J. Heart Fail.11, 847–854 (2009).
   PubMed Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit. Care11(2), R31 (2007).
   PubMed Web of Science ®Google Scholar
• Tang WH, Mullens W. Cardiorenal syndrome in decompensated heart failure. Heart96, 255–260 (2010).
   PubMed Web of Science ®Google Scholar
• Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J. Am. Coll. Cardiol.47, 76–84 (2006).
   PubMed Web of Science ®Google Scholar
• Newsome BB, Warnock DG, McClellan WM et al. Long-term risk of mortality and end-stage renal disease among the elderly after small increases in serum creatinine level during hospitalization for acute myocardial infarction. Arch. Intern. Med.168, 609–616 (2008).
   PubMed Web of Science ®Google Scholar
• Teerlink JR, Metra M, Felker GM et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding Phase IIb study. Lancet373, 1429–1439 (2009).
   PubMed Web of Science ®Google Scholar
• Massie BM, O’Connor CM, Metra M et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med.363, 1419–1428 (2010).
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA293, 572–580 (2005).
   PubMed Web of Science ®Google Scholar
• Aronson D, Hammerman H, Beyar R et al. Serum blood urea nitrogen and long-term mortality in acute ST-elevation myocardial infarction. Int. J. Cardiol.127, 380–385 (2008).
   PubMed Web of Science ®Google Scholar
• Aronson D, Mittleman MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am. J. Med.116, 466–473 (2004).
   PubMed Web of Science ®Google Scholar
• Klein L, Massie BM, Leimberger JD et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ. Heart Fail.1, 25–33 (2008).
   PubMed Web of Science ®Google Scholar
• Kazory A. Emergence of blood urea nitrogen as a biomarker of neurohormonal activation in heart failure. Am. J. Cardiol.106, 694–700 (2010).
   PubMed Web of Science ®Google Scholar
• Coca SG, Parikh CR. Urinary biomarkers for acute kidney injury: perspectives on translation. Clin. J. Am. Soc. Nephrol.3, 481–490 (2008).
   PubMed Web of Science ®Google Scholar
• Damman K, Van Veldhuisen DJ, Navis G et al. Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart96, 1297–1302 (2010).
   PubMed Web of Science ®Google Scholar
• Jungbauer CG, Birner C, Jung B et al. Kidney injury molecule-1 and N-acetyl-ss-D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur. J. Heart Fail.13, 1104–1110 (2011).
   PubMed Web of Science ®Google Scholar
• Damman K, Masson S, Hillege HL et al. Clinical outcome of renal tubular damage in chronic heart failure. Eur. Heart J.32(21), 2705–2712 (2011).
   PubMed Web of Science ®Google Scholar
• Alvelos M, Pimentel R, Pinho E et al. Neutrophil gelatinase-associated lipocalin in the diagnosis of type 1 cardio–renal syndrome in the general ward. Clin. J. Am. Soc. Nephrol.6, 476–481 (2011).
   PubMed Web of Science ®Google Scholar
• Aghel A, Shrestha K, Mullens W, Borowski A, Tang WH. Serum neutrophil gelatinase-associated lipocalin (NGAL) in predicting worsening renal function in acute decompensated heart failure. J. Card. Fail.16, 49–54 (2010).
   PubMed Web of Science ®Google Scholar
• Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated heart failure and the cardiorenal syndrome. Crit. Care Med.36, S75–S88 (2008).
   PubMedGoogle Scholar
• Weinfeld MS, Chertow GM, Stevenson LW. Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am. Heart J.138, 285–290. (1999).
   PubMed Web of Science ®Google Scholar
• Nohria A, Hasselblad V, Stebbins A et al. Cardiorenal interactions: insights from the ESCAPE trial. J. Am. Coll. Cardiol.51, 1268–1274 (2008).
   PubMed Web of Science ®Google Scholar
• Ljungman S, Laragh JH, Cody RJ. Role of the kidney in congestive heart failure. Relationship of cardiac index to kidney function. Drugs39(Suppl. 4), 10–21; discussion: 22–14 (1990).
   PubMedGoogle Scholar
• Rosario LB, Stevenson LW, Solomon SD, Lee RT, Reimold SC. The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. J. Am. Coll. Cardiol.32, 1819–1824 (1998).
   PubMedGoogle Scholar
• Stevenson LW, Brunken RC, Belil D et al. Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced heart failure. J. Am. Coll. Cardiol.15, 174–180 (1990).
   PubMed Web of Science ®Google Scholar
• Firth JD, Raine AE, Ledingham JG. Raised venous pressure: a direct cause of renal sodium retention in oedema? Lancet1(8593), 1033–1035 (1988).
   PubMed Web of Science ®Google Scholar
• Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J. Am. Coll. Cardiol.53, 582–588 (2009).
   PubMed Web of Science ®Google Scholar
• Fiksen-Olsen MJ, Strick DM, Hawley H, Romero JC. Renal effects of angiotensin II inhibition during increases in renal venous pressure. Hypertension19, II137–II141 (1992).
   Google Scholar
• Kastner PR, Hall JE, Guyton AC. Renal hemodynamic responses to increased renal venous pressure: role of angiotensin II. Am. J. Physiol.243, F260–F264 (1982).
   Google Scholar
• Gelman S. Venous function and central venous pressure: a physiologic story. Anesthesiology108, 735–748 (2008).
   PubMed Web of Science ®Google Scholar
• Mohmand H, Goldfarb S. Renal dysfunction associated with intra-abdominal hypertension and the abdominal compartment syndrome. J. Am. Soc. Nephrol.22, 615–621 (2011).
   PubMed Web of Science ®Google Scholar
• De Waele JJ, De Laet I, Kirkpatrick AW, Hoste E. Intra-abdominal hypertension and abdominal compartment syndrome. Am. J. Kidney Dis.57, 159–169 (2011).
   PubMedGoogle Scholar
• Bradley SE, Bradley GP. The effect of increased intra-abdominal pressure on renal function in man. J. Clin. Invest.26, 1010–1022 (1947).
   PubMed Web of Science ®Google Scholar
• Doty JM, Saggi BH, Sugerman HJ et al. Effect of increased renal venous pressure on renal function. J. Trauma47, 1000–1003 (1999).
   PubMed Web of Science ®Google Scholar
• Bloomfield GL, Blocher CR, Fakhry IF, Sica DA, Sugerman HJ. Elevated intra-abdominal pressure increases plasma renin activity and aldosterone levels. J. Trauma42, 997–1004; discussion 1004–1005 (1997).
   PubMed Web of Science ®Google Scholar
• Mullens W, Abrahams Z, Skouri HN et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J. Am. Coll. Cardiol.51, 300–306 (2008).
   PubMed Web of Science ®Google Scholar
• Mullens W, Abrahams Z, Francis GS, Taylor DO, Starling RC, Tang WH. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J. Card. Fail.14, 508–514 (2008).
   Google Scholar
• Sarraf M, Masoumi A, Schrier RW. Cardiorenal syndrome in acute decompensated heart failure. Clin. J. Am. Soc. Nephrol.4, 2013–2026 (2009).
   PubMed Web of Science ®Google Scholar
• Triposkiadis F, Karayannis G, Giamouzis G, Skoularigis J, Louridas G, Butler J. The sympathetic nervous system in heart failure physiology, pathophysiology, and clinical implications. J. Am. Coll. Cardiol.54, 1747–1762 (2009).
   PubMed Web of Science ®Google Scholar
• Bock JS, Gottlieb SS. Cardiorenal syndrome: new perspectives. Circulation121, 2592–2600 (2010).
   PubMed Web of Science ®Google Scholar
• Smilde TD, Damman K, van der Harst P et al. Differential associations between renal function and ‘modifiable’ risk factors in patients with chronic heart failure. Clin. Res. Cardiol.98, 121–129 (2009).
   PubMed Web of Science ®Google Scholar
• Smilde TD, Hillege HL, Navis G, Boomsma F, de Zeeuw D, van Veldhuisen DJ. Impaired renal function in patients with ischemic and nonischemic chronic heart failure: association with neurohormonal activation and survival. Am. Heart J.148, 165–172 (2004).
   Google Scholar
• Zile MR, Bennett TD, St John Sutton M et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation118, 1433–1441 (2008).
   PubMed Web of Science ®Google Scholar
• Aronson D, Eitan A, Dragu R, Burger AJ. Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure. Circ. Heart Fail.4, 644–650 (2011).
   Google Scholar
• Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. Am. J. Med.119, S3–S10 (2006).
   PubMed Web of Science ®Google Scholar
• Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J. Am. Coll. Cardiol.56, 1527–1534 (2010).
   PubMed Web of Science ®Google Scholar
• Damman K, Navis G, Smilde TD et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur. J. Heart Fail.9, 872–878 (2007).
   PubMed Web of Science ®Google Scholar
• Johnson W, Omland T, Hall C et al. Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure. J. Am. Coll. Cardiol.39, 1623–1629 (2002).
   PubMed Web of Science ®Google Scholar
• Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am. Heart J.138, 849–855 (1999).
   PubMed Web of Science ®Google Scholar
• Ahmed A, Husain A, Love TE et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur. Heart J.27, 1431–1439 (2006).
   PubMed Web of Science ®Google Scholar
• Felker GM, O’Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ. Heart Fail.2, 56–62 (2009).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Follath F, Ponikowski P et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur. J. Heart Fail.12, 423–433 (2010).
   PubMed Web of Science ®Google Scholar
• Felker GM, Lee KL, Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med.364, 797–805 (2011).
   PubMed Web of Science ®Google Scholar
• Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA287, 1541–1547 (2002).
   PubMed Web of Science ®Google Scholar
• Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Circulation108, 492–497 (2003).
   PubMed Web of Science ®Google Scholar
• Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization. Circulation108, 367–372 (2003).
   PubMed Web of Science ®Google Scholar
• Abraham WT, Adams KF, Fonarow GC et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Am. Coll. Cardiol.46, 57–64 (2005).
   PubMed Web of Science ®Google Scholar
• Ungar A, Fumagalli S, Marini M et al. Renal, but not systemic, hemodynamic effects of dopamine are influenced by the severity of congestive heart failure. Crit. Care Med.32, 1125–1129 (2004).
   Google Scholar
• Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation117, 200–205 (2008).
   PubMed Web of Science ®Google Scholar
• Beregovich J, Bianchi C, Rubler S, Lomnitz E, Cagin N, Levitt B. Dose-related hemodynamic and renal effects of dopamine in congestive heart failure. Am. Heart J.87, 550–557 (1974).
   PubMed Web of Science ®Google Scholar
• MacGregor DA, Smith TE, Prielipp RC, Butterworth JF, James RL, Scuderi PE. Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology92, 338–346 (2000).
   PubMed Web of Science ®Google Scholar
• Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann. Intern. Med.142, 510–524 (2005).
   PubMed Web of Science ®Google Scholar
• Kellum JA, Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit. Care Med.29, 1526–1531 (2001).
   PubMed Web of Science ®Google Scholar
• Hunt SA, Abraham WT, Chin MH et al. 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and Lung Transplantation. J. Am. Coll. Cardiol.53, e1–e90 (2009).
   Google Scholar
• Goldhaber JI, Hamilton MA. Role of inotropic agents in the treatment of heart failure. Circulation121, 1655–1660 (2010).
   Google Scholar
• Wang DJ, Dowling TC, Meadows D et al. Nesiritide does not improve renal function in patients with chronic heart failure and worsening serum creatinine. Circulation110, 1620–1625 (2004).
   PubMed Web of Science ®Google Scholar
• O’Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med.365, 32–43 (2011).
   PubMed Web of Science ®Google Scholar
• Mullens W, Abrahams Z, Francis GS et al. Sodium nitroprusside for advanced low-output heart failure. J. Am. Coll. Cardiol.52, 200–207 (2008).
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G et al. EESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart Fail.10, 933–989 (2008).
   PubMed Web of Science ®Google Scholar
• Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation104, 1985–1991 (2001).
   PubMed Web of Science ®Google Scholar
• Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am. J. Cardiol.70, 479–487 (1992).
   PubMed Web of Science ®Google Scholar
• Testani JM, Kimmel SE, Dries DL, Coca SG. Prognostic importance of early worsening renal function following initiation of angiotensin converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ. Heart Fail.4(6), 685–691 (2011).
   PubMed Web of Science ®Google Scholar
• Packer M, Lee WH, Medina N, Yushak M, Kessler PD. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic heart failure. Ann. Intern. Med.106, 346–354 (1987).
   PubMed Web of Science ®Google Scholar
• Echemann M, Zannad F, Briancon S et al. Determinants of angiotensin-converting enzyme inhibitor prescription in severe heart failure with left ventricular systolic dysfunction: the EPICAL study. Am. Heart J.139, 624–631 (2000).
   PubMedGoogle Scholar
• Kittleson M, Hurwitz S, Shah MR et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J. Am. Coll. Cardiol.41, 2029–2035 (2003).
   PubMed Web of Science ®Google Scholar
• Shlipak MG, Massie BM. The clinical challenge of cardiorenal syndrome. Circulation110, 1514–1517 (2004).
   PubMed Web of Science ®Google Scholar
• Packer M, Lee WH, Kessler PD. Preservation of glomerular filtration rate in human heart failure by activation of the renin–angiotensin system. Circulation74, 766–774 (1986).
   PubMed Web of Science ®Google Scholar
• Kearney MT, Fox KA, Lee AJ et al. Predicting death due to progressive heart failure in patients with mild-to-moderate chronic heart failure. J. Am. Coll. Cardiol.40, 1801–1808 (2002).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Abraham WT, Albert NM et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur. Heart J.28, 980–988 (2007).
   PubMed Web of Science ®Google Scholar
• Klein L, O’Connor CM, Leimberger JD et al. Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation111, 2454–2460 (2005).
   PubMed Web of Science ®Google Scholar
• Goldberg A, Hammerman H, Petcherski S et al. Prognostic importance of hyponatremia in acute ST-elevation myocardial infarction. Am. J. Med.117, 242–248 (2004).
   PubMed Web of Science ®Google Scholar
• Goldberg A, Hammerman H, Petcherski S et al. Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch. Intern. Med.166, 781–786 (2006).
   PubMedGoogle Scholar
• Goldsmith SR. Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure. Am. J. Cardiol.95, 14–23 (2005).
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Hollenberg NK. Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia. Ann. Intern. Med.100, 777–782 (1984).
   PubMed Web of Science ®Google Scholar
• Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure. Relation to activation of the renin–angiotensin system and hyponatremia. N. Engl. J. Med.310, 347–352 (1984).
   PubMed Web of Science ®Google Scholar
• Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation73, 257–267 (1986).
   PubMed Web of Science ®Google Scholar
• Mettauer B, Rouleau JL, Bichet D et al. Sodium and water excretion abnormalities in congestive heart failure. Determinant factors and clinical implications. Ann. Intern. Med.105, 161–167 (1986).
   Google Scholar
• Lilly LS, Dzau VJ, Williams GH, Rydstedt L, Hollenberg NK. Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J. Clin. Endocrinol. Metab.59, 924–930 (1984).
   PubMedGoogle Scholar
• Mohammed AA, van Kimmenade RR, Richards M et al. Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study. Circ. Heart Fail.3, 354–361 (2010).
   PubMed Web of Science ®Google Scholar
• Packer M, Lee WH, Kessler PD, Medina N, Yushak M, Gottlieb SS. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure. J. Am. Coll. Cardiol.10, 837–844 (1987).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation107, 2690–2696 (2003).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O’Connor CM et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA291, 1963–1971 (2004).
   PubMed Web of Science ®Google Scholar
• Ghali JK, Koren MJ, Taylor JR et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. J. Clin. Endocrinol. Metab.91, 2145–2152 (2006).
   PubMed Web of Science ®Google Scholar
• Aronson D, Verbalis JG, Mueller M, Krum H. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study. Eur. J. Heart Fail.13, 327–336 (2011).
   Google Scholar
• Gheorghiade M, Konstam MA, Burnett JC Jr et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA297, 1332–1343 (2007).
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC Jr et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA297, 1319–1331 (2007).
   PubMed Web of Science ®Google Scholar
• Vallon V, Miracle C, Thomson S. Adenosine and kidney function: potential implications in patients with heart failure. Eur. J. Heart Fail.10, 176–187 (2008).
   PubMed Web of Science ®Google Scholar
• Givertz MM, Massie BM, Fields TK, Pearson LL, Dittrich HC. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J. Am. Coll. Cardiol.50, 1551–1560 (2007).
   PubMed Web of Science ®Google Scholar
• Dittrich HC, Gupta DK, Hack TC, Dowling T, Callahan J, Thomson S. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J. Card. Fail.13, 609–617 (2007).
   PubMed Web of Science ®Google Scholar
• Voors AA, Dittrich HC, Massie BM et al. Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J. Am. Coll. Cardiol.57, 1899–1907 (2011).
   PubMed Web of Science ®Google Scholar
• Kazory A, Ross EA. Contemporary trends in the pharmacological and extracorporeal management of heart failure: a nephrologic perspective. Circulation117, 975–983 (2008).
   PubMed Web of Science ®Google Scholar
• Bart BA. Treatment of congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failure. Circ. Heart Fail.2, 499–504 (2009).
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Guglin ME, Saltzberg MT et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J. Am. Coll. Cardiol.49, 675–683 (2007).
   PubMed Web of Science ®Google Scholar
• Rogers HL, Marshall J, Bock J et al. A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure. J. Card. Fail.14, 1–5 (2008).
   PubMed Web of Science ®Google Scholar
• Shin JT, Dec GW. Ultrafiltration should not replace diuretics for the initial treatment of acute decompensated heart failure. Circ. Heart Fail.2, 505–511 (2009).
   PubMedGoogle Scholar
• Cody RJ, Ljungman S, Covit AB et al. Regulation of glomerular filtration rate in chronic congestive heart failure patients. Kidney Int.34, 361–367 (1988).
   PubMed Web of Science ®Google Scholar
• Packer M, Lee WH, Kessler PD. Preservation of glomerular filtration rate in human heart failure by activation of the renin–angiotensin system. Circulation74, 766–774 (1986).
   PubMed Web of Science ®Google Scholar
• Dupont M, Mullens W, Tang WH. Impact of systemic venous congestion in heart failure. Curr. Heart Fail. Rep.8, 233–241 (2011).
   Google Scholar
• Verma A, Anavekar NS, Meris A et al. The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. J. Am. Coll. Cardiol.50, 1238–1245 (2007).
   Google Scholar
• Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J. Am. Coll. Cardiol.47, 1–8 (2006).
   PubMed Web of Science ®Google Scholar
• Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J. Clin. Invest.83, 336–342 (1989).
   PubMed Web of Science ®Google Scholar
• Levin ER. Endothelins. N. Engl. J. Med.333, 356–363 (1995).
   PubMed Web of Science ®Google Scholar
• Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature324, 473–476 (1986).
   PubMed Web of Science ®Google Scholar
• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N. Engl. J. Med.339, 321–328 (1998).
   PubMed Web of Science ®Google Scholar